{
    "clinical_study": {
        "@rank": "6513", 
        "acronym": "NPC", 
        "arm_group": [
            {
                "arm_group_label": "IInductive chemotherapy + concurrent cisplatin and IMRT", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30 mg/m2\uff0con day 1) repeated every weeks for 6 cycles during radiotherapy."
            }, 
            {
                "arm_group_label": "Inductive chemotherapy + IMRT", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT."
            }
        ], 
        "brief_summary": {
            "textblock": "Concurrent cisplatin-based chemotherapy plus radiotherapy increased the risk of\n      treatment-related death and severe acute toxicity. The survival benefit of adding concurrent\n      chemotherapy to intensity modulated radiation in patients with locoregionally advanced\n      nasopharyngeal carcinoma is unclear. Gemcitabine plus cisplatin chemotherapy combine with\n      radiotherapy was effective and well tolerated by patients with locoregionally advanced NPC."
        }, 
        "brief_title": "Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Nasopharyngeal Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to compare gemcitabine plus cisplatin induction chemotherapy\n      combine intensity-modulated radiotherapy with or without concurrent cisplatin in patients\n      with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to reevaluate the\n      value of concurrent cisplatin when 4 cycles induction chemotherapy (gemcitabine+cisplatin)\n      and IMRT is used."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with newly histologically confirmed non-keratinizing (according to World\n             Health Organization (WHO 2005) histologically type).\n\n          -  A Karnofsky performance status of at least 80;\n\n          -  Tumor staged is according to the 7th American Joint Commission on Cancer edition as\n             Stage III\uff1aT1-2N2M0, T3N0-2M0 Stage IVa\uff1aT4N0-2M0 Stage IVb\uff1aAny T\u3001N3.\n\n          -  Adequate marrow: a WBC \u22653.5\u00d7109 l-1; a platelet count \u2265100\u00d7109 l-1; and hemoglobin\n             levels \u2265100 g/l.\n\n          -  Normal liver function test: Alanine Aminotransferase (ALT)\u3001Aspartate Aminotransferase\n             (AST) <1.5\u00d7upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP)\n             \u22642.5\u00d7ULN, and bilirubin \u2264ULN.\n\n          -  Adequate renal function: a creatinine clearance rate of at least 60 mL/min.\n\n          -  Patients must be informed of the investigational nature of this study and give\n             written informed consent.\n\n        Exclusion Criteria:\n\n          -  WHO Type keratinizing squamous cell carcinoma.\n\n          -  Age >65 years or <18 years.\n\n          -  Distant metastasis,\n\n          -  Treatment with palliative intent.\n\n          -  Pregnancy or lactation.\n\n          -  a history of previous radiotherapy in the nasopharyngeal region or previous\n             chemotherapy.\n\n          -  history of renal disease, unstable cardiac disease requiring treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854203", 
            "org_study_id": "ChiECRCT-2013003"
        }, 
        "intervention": [
            {
                "arm_group_label": "IInductive chemotherapy + concurrent cisplatin and IMRT", 
                "description": "Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2\uff0con day 1) repeated every week for 6 cycles during radiotherapy.", 
                "intervention_name": "Inductive chemotherapy + concurrent cisplatin and IMRT", 
                "intervention_type": "Drug", 
                "other_name": "Gemcitabine and cisplatin"
            }, 
            {
                "arm_group_label": "Inductive chemotherapy + IMRT", 
                "description": "Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy  with IMRT.", 
                "intervention_name": "Inductive chemotherapy + IMRT", 
                "intervention_type": "Drug", 
                "other_name": "Gemcitabine and cisplatin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cisplatin", 
            "neoadjuvant chemotherapy", 
            "intensity-modulated radiation therapy", 
            "concurrent chemoradiotherapy"
        ], 
        "lastchanged_date": "July 28, 2013", 
        "location": [
            {
                "contact": {
                    "email": "lijj@sysucc.org.cn", 
                    "last_name": "Jian-jun Li, MD", 
                    "phone": "+862087343381"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510060"
                    }, 
                    "name": "Cancer Center,Sun Yat-sen University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510060"
                    }, 
                    "name": "State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University"
                }, 
                "investigator": [
                    {
                        "last_name": "Jian-jun Li, M.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Li-zhi Liu, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated Radiotherapy With or Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma", 
        "other_outcome": {
            "description": "Rates of toxicity will also be compared. Rates will be compared by the chi-square test.The Chemotherapy toxicity include thrombocytopenia, leukocytopenia , anemia, granulocytopenia,damage to hepatic function, damage to renal function,constipation, diarrhea,vomiting and rash. The  radiotherapy toxicities include  mucositis, radiation dermatitis,dysphagia, xerostomia, skin fibrosis, trismus, hearing loss ane cranial neuropathy.", 
            "measure": "Rates of toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "3-years"
        }, 
        "overall_contact": {
            "email": "lijj@sysucc.org.cn", 
            "last_name": "Janjun Li, M.D.", 
            "phone": "+86+13829745245"
        }, 
        "overall_contact_backup": {
            "email": "liulizh@sysucc.org.cn", 
            "last_name": "Lizhi Liu, M.D.", 
            "phone": "+86+13660528375"
        }, 
        "overall_official": [
            {
                "affiliation": "Sun Yat-sen University", 
                "last_name": "yong Su, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Sun Yat-sen University", 
                "last_name": "Janjun Li, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Sun Yat-sen University", 
                "last_name": "Lizhi Liu, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Overall survival is calculated from randomization to death from any cause.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "3-year"
            }, 
            {
                "description": "Failure-free survival is calculated from the date of randomization to the date of the first failure at any site.", 
                "measure": "Failure-free survival", 
                "safety_issue": "No", 
                "time_frame": "3-year"
            }, 
            {
                "description": "the latency to the first local failure", 
                "measure": "Locoregional failure-free survival", 
                "safety_issue": "No", 
                "time_frame": "3-year"
            }, 
            {
                "description": "The latency to the first remote failure", 
                "measure": "Distant failure-free survival", 
                "safety_issue": "No", 
                "time_frame": "3-year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854203"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Jian-jun Li", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Difference in the complete response rates between the two treatment arms", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after the completion of therapy"
        }, 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}